
    
      This study is a phase IIb, multicenter, multi-national, double-blind, randomized,
      parallel-arm, placebo-controlled study to evaluate the effect of 5 dose levels of CSJ117
      (0.5; 1; 2; 4 and 8 mg) inhaled once daily compared with placebo, when added to standard of
      care asthma therapy in adult subjects with inadequately controlled asthma despite medium to
      high dose ICS plus LABA. Approximately 625 patients will be randomized into this study.
    
  